These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32231295)

  • 1. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
    Krystal AD; Pizzagalli DA; Smoski M; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu D; Murrough JW; Yang H; Weiner RD; Calabrese JR; Sanacora G; Hermes G; Keefe RSE; Song A; Goodman W; Szabo ST; Whitton AE; Gao K; Potter WZ
    Nat Med; 2020 May; 26(5):760-768. PubMed ID: 32231295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).
    Pizzagalli DA; Smoski M; Ang YS; Whitton AE; Sanacora G; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu DV; Murrough JW; Yang H; Weiner RD; Calabrese JR; Goodman W; Potter WZ; Krystal AD
    Neuropsychopharmacology; 2020 Sep; 45(10):1656-1663. PubMed ID: 32544925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression.
    Fava M; Mazzone E; Freeman M; Flynn M; Judge H; Hoeppner B; Hock RS; Shui A; Macaluso M; Morrison MF; Carpenter LL; Shelton R; Zajecka J; Papakostas GI
    Ann Clin Psychiatry; 2020 Feb; 32(4):18-26. PubMed ID: 33125454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice.
    Jacobson ML; Wulf HA; Browne CA; Lucki I
    Psychopharmacology (Berl); 2020 Dec; 237(12):3715-3728. PubMed ID: 32894343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aticaprant, a kappa opioid receptor antagonist, and the recovered 'interest and pleasure' in the concept of major depressive disorder.
    Demyttenaere K
    Eur Arch Psychiatry Clin Neurosci; 2024 Jul; ():. PubMed ID: 38969753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.
    Jones JD; Babalonis S; Marcus R; Vince B; Kelsh D; Lofwall MR; Fraser H; Paterson B; Martinez S; Martinez DM; Nunes EV; Walsh SL; Comer SD
    Addict Biol; 2020 Jul; 25(4):e12799. PubMed ID: 31240842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
    Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
    Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
    PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis.
    Murata Y; Song M; Kikuchi H; Hisamichi K; Xu XL; Greenspan A; Kato M; Chiou CF; Kato T; Guzzo C; Thurmond RL; Ohtsuki M; Furue M
    J Dermatol; 2015 Feb; 42(2):129-39. PubMed ID: 25491792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder.
    Browne CA; Wulf H; Lucki I
    Handb Exp Pharmacol; 2022; 271():493-524. PubMed ID: 33580854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
    Carlezon WA; Krystal AD
    Depress Anxiety; 2016 Oct; 33(10):895-906. PubMed ID: 27699938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.
    Rorick-Kehn LM; Witcher JW; Lowe SL; Gonzales CR; Weller MA; Bell RL; Hart JC; Need AB; McKinzie JH; Statnick MA; Suico JG; McKinzie DL; Tauscher-Wisniewski S; Mitch CH; Stoltz RR; Wong CJ
    Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25637376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.
    Krystal AD; Pizzagalli DA; Mathew SJ; Sanacora G; Keefe R; Song A; Calabrese J; Goddard A; Goodman W; Lisanby SH; Smoski M; Weiner R; Iosifescu D; Nurnberger J; Szabo S; Murrough J; Shekhar A; Potter W
    Nat Rev Drug Discov; 2018 Dec; 18(1):82-84. PubMed ID: 30591715
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
    Jackson KJ; Jackson A; Carroll FI; Damaj MI
    Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
    Costi S; Morris LS; Kirkwood KA; Hoch M; Corniquel M; Vo-Le B; Iqbal T; Chadha N; Pizzagalli DA; Whitton A; Bevilacqua L; Jha MK; Ursu S; Swann AC; Collins KA; Salas R; Bagiella E; Parides MK; Stern ER; Iosifescu DV; Han MH; Mathew SJ; Murrough JW
    Am J Psychiatry; 2021 May; 178(5):437-446. PubMed ID: 33653118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NIMH 'Fast-Fail Trials' (FAST) Initiative: Rationale, Promise, and Progress.
    Grabb MC; Hillefors M; Potter WZ
    Pharmaceut Med; 2020 Aug; 34(4):233-245. PubMed ID: 32705569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence.
    Reed B; Butelman ER; Fry RS; Kimani R; Kreek MJ
    Neuropsychopharmacology; 2018 Mar; 43(4):739-750. PubMed ID: 28857070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anhedonia, depression, anxiety, and craving in opioid dependent patients stabilized on oral naltrexone or naltrexone implant].
    Krupitsky EM; Zvartau EE; Blokhina EA; Verbitskaya EV; Wahlgren VY; Tsoy-Podosenin MV; Bushara NM; Burakov AM; Masalov DV; Romanova TN; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Sulimov GY; Pecoraro A; Woody G
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(1. Vyp. 2):26-33. PubMed ID: 29658501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.